ConductScience.org, home

Paper17538165

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.

Herrmann R and 21 others. J Clin Oncol, 2007. Cited by 492 papers, by iCite.

Cite this record

ConductScience Library. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Papers, record 17538165. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538165

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
492
iCite
Relative citation ratio, by iCite
11.9
iCite
Revised in PubMed
2024-12-19
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Herrmann RRichard
2Bodoky GGyörgy
3Ruhstaller TThomas
4Glimelius BBengt
5Bajetta EEmilio
6Schüller JJohannes
7Saletti PPiercarlo
8Bauer JJean
9Figer AArie
10Pestalozzi BBernhard
11Köhne CHClaus-Henning
12Mingrone WWalter
13Stemmer SMSalomon M
14Tàmas KKarin
15Kornek GVGabriela V
16Koeberle DDieter
17Cina SSusanne
18Bernhard JJürg
19Dietrich DDaniel
20Scheithauer WWerner

Source PubMed

See all 22 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
DeoxycytidineMajor topic
FluorouracilMajor topic
Pancreatic NeoplasmsMajor topic
Capecitabine
Female
Humans
Male
Gemcitabine

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00030732Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic CancerResults

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17538158Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?https://conductscience.org/library/papers/17538158

Source PubMed

Download CSV of comments and corrections

Cited by239

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 492 citations.

PMIDTitleJournalYearIn PapersSource
42448976Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.Ann Surg Oncol2026https://conductscience.org/library/papers/42448976PubMed
41731281Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here.Drugs2026https://conductscience.org/library/papers/41731281PubMed
41569206Real World Evidence of Clinical Outcomes of First-Line Chemotherapy in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Patients.Asian Pac J Cancer Prev2026https://conductscience.org/library/papers/41569206PubMed
41058695Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreatic cancer: a retrospective analysis.Front Immunol2025https://conductscience.org/library/papers/41058695PubMed
40806185Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies.Int J Mol Sci2025https://conductscience.org/library/papers/40806185PubMed
40075310Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer.BMC Cancer2025https://conductscience.org/library/papers/40075310PubMed
40004658Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review.J Clin Med2025https://conductscience.org/library/papers/40004658PubMed
39712186Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analysis.Front Med (Lausanne)2024https://conductscience.org/library/papers/39712186PubMed
39635901Chemotherapy and radiotherapy for advanced pancreatic cancer.Cochrane Database Syst Rev2024https://conductscience.org/library/papers/39635901PubMed
39551595Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review.BMJ Open2024https://conductscience.org/library/papers/39551595PubMed
39390609Consensus, debate, and prospective on pancreatic cancer treatments.J Hematol Oncol2024https://conductscience.org/library/papers/39390609PubMed
39330013Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions.Curr Oncol2024https://conductscience.org/library/papers/39330013PubMed
38681566Efficacy and safety of first-line chemotherapies for patients with advanced pancreatic ductal adenocarcinoma: A systematic review and network meta-analysis.Heliyon2024https://conductscience.org/library/papers/38681566PubMed
37869244Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the First-Line Treatment for Pancreatic Cancer: A Systematic Review and Meta-Analysis.World J Oncol2023https://conductscience.org/library/papers/37869244PubMed
37007078Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects.Front Oncol2023https://conductscience.org/library/papers/37007078PubMed
36235333Chemical Constituents of Callistemon subulatus and Their Anti-Pancreatic Cancer Activity against Human PANC-1 Cell Line.Plants (Basel)2022https://conductscience.org/library/papers/36235333PubMed
36092340The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis.J Gastrointest Oncol2022https://conductscience.org/library/papers/36092340PubMed
35852758Recent Update on Active Biological Molecules in Generating the Anticancerous Therapeutic Potential of Garcinia mangostana.Appl Biochem Biotechnol2022https://conductscience.org/library/papers/35852758PubMed
35099549Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.JAMA Netw Open2022https://conductscience.org/library/papers/35099549PubMed
35052828Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine.Biomedicines2022https://conductscience.org/library/papers/35052828PubMed

See all 239 cited byDownload CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CAPECITABINECHEMBL1773Results1https://conductscience.org/library/drugs/CHEMBL1773ChEMBL
GEMCITABINECHEMBL888Results1https://conductscience.org/library/drugs/CHEMBL888ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17538165

GET https://conductscience.org/api/papers/v1/17538165/authors?page=2